Expanding the Reach of AmplideX Technology

Asuragen’s unique and proprietary AmplideX® chemistries allows for simple and streamlined solutions for analysis of complex genomic targets. Visit our booth at the 2018 ACMG Annual Meeting to learn more about our expanding Genetics portfolio, including kits for genes implicated in myotonic dystrophy, spinal muscular atrophy and Huntington’s disease.

VISIT US AT BOOTH #1402

Meet the Asuragen team and learn more about our current and upcoming genetic kit offerings. 

POSTER SESSION

Thursday, April 12
10:00 AM-11:30 AM

Poster 377
A Rapid, High-throughput PCR Fragment-sizing Assay for Quantifying Spinal Muscular Atrophy (SMN1, SMN2) Copy Numbers
Presenting Author: Stela Filipovic-Sadic

Poster 439
Robust PCR/CE Assay Using AmplideX Technology for Rapid and Accurate Genotyping of CAG Repeat Expansions in HTT
Presenting Author: Julie Thibert


View our previously presented posters to learn even more about our upcoming AmplideX launches:

Presented at ASHG 2017
Development of a Unified DMPK and CNBP PCR Workflow for Determining Repeat Expansions Relevant to Myotonic Dystrophies
Click here to view the full poster

Clinical Correlations of a Streamlined Molecular Assay Based on Amplidex PCR/CE Technology that Determines Repeat Size for Both Normal and Expanded Alleles in DMPK for Myotonic Dystrophy Type 1
Click here to view the full poster


Discover how our current portfolio of AmplideX solutions can empower your research and enhance your testing capabilities:
AmplideX® PCR/CE FMR1 Reagents
AmplideX® mPCR FMR1
AmplideX® FMR1 Controls
AmplideX® PCR/CE C9orf72 Kit
AmplideX® PCR/CE TOMM40 Kit

Back To
Top